Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Cash from Financing Activities: 2010-2024

Historic Cash from Financing Activities for EyePoint Pharmaceuticals (EYPT) over the last 15 years, with Dec 2024 value amounting to $164.0 million.

  • EyePoint Pharmaceuticals' Cash from Financing Activities rose 86.91% to -$7.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$19.8 million, marking a year-over-year decrease of 137.60%. This contributed to the annual value of $164.0 million for FY2024, which is 12.32% down from last year.
  • Latest data reveals that EyePoint Pharmaceuticals reported Cash from Financing Activities of $164.0 million as of FY2024, which was down 12.32% from $187.1 million recorded in FY2023.
  • EyePoint Pharmaceuticals' 5-year Cash from Financing Activities high stood at $216.9 million for FY2021, and its period low was -$690,000 during FY2022.
  • Its 3-year average for Cash from Financing Activities is $116.8 million, with a median of $164.0 million in 2024.
  • In the last 5 years, EyePoint Pharmaceuticals' Cash from Financing Activities slumped by 100.32% in 2022 and then skyrocketed by 27,211.59% in 2023.
  • Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Cash from Financing Activities stood at $37.5 million in 2020, then surged by 478.53% to $216.9 million in 2021, then slumped by 100.32% to -$690,000 in 2022, then skyrocketed by 27,211.59% to $187.1 million in 2023, then dropped by 12.32% to $164.0 million in 2024.